Blockbusters brace for competition

Posted 2 June 2025 AM 

The TGA has approved three new drugs – two of which will be considered for PBS listing next month – along with a long list of generics targeting big brands, such as Bayer’s Elyea.

Galderma’s IL-31 inhibitor Nemluvio has been approved for two indications, including moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/ or topical calcineurin inhibitors in adults and patients aged 12 years and above who weigh at least 30kg, who are candidates for systemic therapy.

To see the whole article, please login